Welcome to Volume 14 of Neurodegenerative Disease Management

Figures & data

Table 1. The top five most read articles in Neurodegenerative Disease Management 2023.

Rank	Article type	Title	Study	Volume (issue)	Ref.
1	Review	Updates and advances in multiple sclerosis neurotherapeutics	M Amin & CM Hersh	13(1)	[1]
2	Plain Language Summary of Publication	The amyloid-β pathway in Alzheimer’s disease: a plain language summary	H Hampel et al.	13(3)	[2]
3	Plain Language Summary of Publication	A plain language summary of what clinical studies can tell us about the safety of evobrutinib – a potential treatment for multiple sclerosis	X Montalban et al.	13(4)	[3]
4	Plain Language Summary of Publication	A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets	K Schmierer et al.	13(1)	[4]
5	Plain Language Summary of Publication	A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry	T Spelman et al.	13(4)	[5]

Table 2. The top five most cited articles in Neurodegenerative Disease Management 2023.

Rank	Citations	Article type	Title	Study	Volume (issue)	Ref.
1	4	Systematic Review	The effect of auditory cues on gait variability in people with Parkinson’s disease and older adults: a systematic review	EC Harrison & GM Earhart	13(2)	[6]
2	4	Research Article	Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson’s disease	MM Anwar & MH Fathi	13(2)	[7]
3	3	Plain Language Summary of Publication	The amyloid-β pathway in Alzheimer’s disease: a plain language summary diagnostic biomarkers for colorectal cancer patients	H Hampel et al.	13(3)	[2]
4	2	Short Communication	Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users	CB Vaughn et al.	13(3)	[8]
5	1	Research Article	Wearable activity monitors to support physical activity interventions in neurodegenerative disease: a feasibility study	H-J Steffi Shih et al.	13(3)	[9]

Table 3. The top five articles with the most social media engagement in Neurodegenerative Disease Management 2023.

Rank	Article type	Title	Study	Volume (issue)	Ref.
1	Plain Language Summary of Publication	The amyloid-β pathway in Alzheimer’s disease: a plain language summary	H Hampel et al.	13(3)	[2]
2	Research Article	Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson’s disease	MM Anwar & MH Fathi	13(2)	[7]
3	Plain Language Summary of Publication	A plain language summary of what clinical studies can tell us about the safety of evobrutinib – a potential treatment for multiple sclerosis	X Montalban et al.	13(4)	[10]
4	Plain Language Summary of Publication	A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study	G Giovannoni et al.	13(5)	[11]
5	Plain Language Summary of Publication	A study of once-a-week donepezil transdermal system’s bioequivalence to oral donepezil in healthy volunteers: a plain language summary	R Braeckman & C Oh	13(6)	[12]

Figure 1. Manuscript accepted by country.

Figure 2. Readership demographic.

Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener. Dis. Manag. 13(1), 47–70 (2023).

 PubMed Web of Science ®Google Scholar

Hampel H, Hu Y, Hardy J et al. The amyloid-β pathway in Alzheimer’s disease: a plain language summary. Neurodegener. Dis. Manag. 13(3), 141–149 (2023).

 PubMed Web of Science ®Google Scholar

Montalban X, Wallace D, Genovese MC. A plain language summary of what clinical studies can tell us about the safety of evobrutinib – a potential treatment for multiple sclerosis. Neurodegener. Dis. Manag. 13(4), 207–213 (2023).

 PubMedGoogle Scholar

Schmierer K, Wiendl H, Oreja-Guevara C et al. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Neurodegener. Dis. Manag. 13(1), 15–21 (2023).

 PubMed Web of Science ®Google Scholar

Spelman T, Ozakbas S, Alroughani R et al. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. Neurodegener. Dis. Manag. 13(4), 215–221 (2023).

 PubMed Web of Science ®Google Scholar

Harrison EC, Earhart GM. The effect of auditory cues on gait variability in people with Parkinson’s disease and older adults: a systematic review. Neurodegener. Dis. Manag. 13(2), 113–128 (2023).

 PubMed Web of Science ®Google Scholar

Anwar MM, Fathi MH. Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson’s disease. Neurodegener. Dis. Manag. 13(2), 85–99 (2023).

 PubMed Web of Science ®Google Scholar

Vaughn CB, Kavak KS, Jakimovski D et al. Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users. Neurodegener. Dis. Manag. 13(3), 151–159 (2023).

 PubMed Web of Science ®Google Scholar

Shih H-JS, Quinn L, Morgan-Jones P et al. Wearable activity monitors to support physical activity interventions in neurodegenerative disease: a feasibility study. Neurodegener. Dis. Manag. 13(3), 177–189 (2023).

 PubMed Web of Science ®Google Scholar

Montalban X, Wallace D, Genovese MC et al. A plain language summary of what clinical studies can tell us about the safety of evobrutinib – a potential treatment for multiple sclerosis. Neurodegener. Dis. Manag. 13(4), 207–213 (2023).

 PubMedGoogle Scholar

Giovannoni G, Boyko A, Correale J et al. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: the CLASSIC-MS study. Neurodegener. Dis. Manag. 13(5), 261–268 (2023).

 PubMed Web of Science ®Google Scholar

Braeckman R, Oh C. A study of once-a-week donepezil transdermal system’s bioequivalence to oral donepezil in healthy volunteers: a plain language summary. Neurodegener. Dis. Manag. 13(6), 303–313 (2023).

 PubMed Web of Science ®Google Scholar